title: Empagliflozin's Fuel Hypothesis: Not so Soon.
abstract: The EMPA-REG OUTCOME trial (Zinman et al., 2015) established cardioprotective effects of empagliflozin in high-risk diabetic patients, but the underlying mechanisms remain elusive. A recent hypothesis proposed that increased ketone oxidation contributed to the effect, but several caveats indicate that the role of myocardial ketone oxidation is far from clear.
authors: Cardiovascular Translational Science Institute, University of Alberta, Edmonton, AB T6G 2S2, Canada. Electronic address: gary.lopaschuk@ualberta.ca.
authors: Gary D
authors: GD
authors: Lopaschuk
authors: Division of Cardiac Surgery, Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, ON M5S, Canada. Electronic address: vermasu@smh.ca.
authors: Subodh
authors: S
authors: Verma
mesh_terms: D003920:Diabetes Mellitus; D006801:Humans; D007004:Hypoglycemic Agents; D009206:Myocardium
chemical_list: D007004:Hypoglycemic Agents